Theraclion SA (TCLIF)
OTCMKTS · Delayed Price · Currency is USD
0.3200
+0.3198 (159,900.00%)
At close: Aug 26, 2024
Theraclion Revenue
Theraclion had revenue of 944.00K EUR in the half year ending June 30, 2025, a decrease of -3.77%. This brings the company's revenue in the last twelve months to 1.87M, up 210.90% year-over-year. In the year 2024, Theraclion had annual revenue of 830.21K, down -54.44%.
Revenue (ttm)
1.87M EUR
Revenue Growth
+210.90%
P/S Ratio
15.15
Revenue / Employee
58.57K EUR
Employees
32
Market Cap
33.34M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 830.21K | -992.01K | -54.44% |
| Dec 31, 2023 | 1.82M | 586.77K | 47.49% |
| Dec 31, 2022 | 1.24M | -245.50K | -16.58% |
| Dec 31, 2021 | 1.48M | 736.95K | 99.05% |
| Dec 31, 2020 | 744.00K | -2.39M | -76.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |